Full Breakdown
Trump’s Eli Lilly Stock Purchases Overlap With Administration’s GLP-1 Push
5/26/2026, 12:19:57 AM
Core Event: Stock Buys Coincide With Pro-Lilly Policies
Between January 1 and March 31 2026, disclosures signed by President Donald Trump recorded seven purchases of Eli Lilly stock and one purchase of West Pharmaceutical Services stock. The Lilly purchases totalled up to $680,000; the West Pharmaceutical buy was valued between $250,000 and $500,000. During the same period the Trump administration advanced a Medicare pilot (BALANCE) offering GLP-1 drugs for $50 per month, launched the TrumpRx portal that lists Lilly’s Zepbound at $299 per month, intensified a crackdown on “compounded” GLP-1s, and secured FDA approval of Lilly’s Foundayo weight-loss pill under Commissioner Marty Makary’s priority-voucher program.
Background & Context: GLP-1 Surge and Policy Shifts
GLP-1 medicines such as Zepbound and Foundayo treat diabetes and obesity and have become central to U.S. weight-loss therapy. In 2025, 12 % of adults reported using a GLP-1, yet 56 % said the drugs were unaffordable. Historically Medicare excluded obesity drugs; the BALANCE pilot represents the first systematic effort to reimburse them at a flat $50 monthly rate. The FDA’s accelerated approval of Foundayo (50 days after filing) and the crackdown on cheaper compounded versions further cleared market obstacles for Lilly’s branded products.
Key Figures & Groups
- President Donald Trump – investor and policy driver.
- Eli Lilly & Co. – manufacturer of Zepbound, Foundayo, and LillyDirect telemedicine service.
- West Pharmaceutical Services – maker of injectable devices used for GLP-1 delivery.
- Centers for Medicare & Medicaid Services (CMS) – operator of the BALANCE pilot.
- U.S. Food and Drug Administration (FDA) – granted priority-voucher approval; Commissioner Marty Makary oversaw the process.
- Legal ethicist Kathleen Clark (Washington University) – ethics commentator.
- Sen. Andy Kim (D-N.J.) – congressional critic.
- Trump Organization – entity managing the president’s investments.
Data & Statistics
- Lilly’s 2025 revenue: $65 billion, up $20 billion from 2024; projected 2026 revenue > $80 billion.
- GLP-1 market share: $65 billion of Lilly’s total revenue.
- Medicare pilot price: $50 per month for participating GLP-1s.
- Trump’s disclosed trades in Q1 2026: ? 3,600 transactions across multiple sectors.
- Four of the seven Lilly purchases are marked “unsolicited” in the filings.
Official Statements & Responses
The Trump Organization asserted that the investments are managed by independent brokers and that neither the president nor his children direct specific trades. Eric Trump reiterated that any claim of family-directed stock activity “would be a lie and blatantly false.” A Department of Health and Human Services spokesperson declined comment, referring reporters to the White House, which in turn redirected inquiries to the Trump Organization. Eli Lilly and West Pharmaceutical Services did not provide remarks.
Criticism & Opposition
Ethics scholars warn that a president profiting from policies that affect a company’s stock erodes public trust. Legal ethicist Kathleen Clark emphasized the need for the public to believe government actions serve the common good, not personal enrichment. Democratic lawmakers have called for legislation banning presidential stock trading; Sen. Andy Kim labeled Trump “the ultimate con man” and urged a ban.
Conflicting Reports & Gaps
The disclosures do not clarify whether Trump personally authorized any trades; the meaning of “unsolicited” remains undefined by the Office of Government Ethics. No comment was received from Lilly, West Pharmaceutical, HHS, or the Office of Government Ethics, leaving key details about decision-making processes unverified.
Verbatim Quotes
- “I probably should” take them. — Donald Trump, interview with *The New York Times*
- “A president who buys or sells the stock of a company whose value is affected by his administration’s actions undermines the public’s trust in two ways,” — Kathleen Clark, legal ethicist, Washington University
- “This approval demonstrates what the FDA can achieve when we eliminate delays and prioritize fast and thorough work from the agency and industry partners,” — Marty Makary, former FDA Commissioner
- “Trump is the ultimate con man — rig the game, manipulate the rules, and reap the benefits,” — Sen. Andy Kim (D-N.J.) on X
- “Guidance anticipates favorable impact from Medicare coverage of obesity medications by 7/1/26,” — TD Cowen analysts
What’s Next
Democratic leaders are drafting a bill that would prohibit presidents from owning or trading individual stocks, with a target introduction in 2027. Ongoing ethics investigations may examine the timing of the BALANCE pilot and FDA approvals relative to the disclosed trades. Congressional oversight hearings are expected to address broader concerns about presidential financial conflicts of interest.
